Cargando…
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on...
Autores principales: | Yi, Chengxiang, He, Yayi, Xia, Haoran, Zhang, Helin, Zhang, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735538/ https://www.ncbi.nlm.nih.gov/pubmed/31564915 http://dx.doi.org/10.2147/OTT.S218321 |
Ejemplares similares
-
Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
por: Roller, John F., et al.
Publicado: (2022) -
Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective
por: Park, Sehhoon
Publicado: (2023) -
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020) -
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023) -
Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)